scholarly journals Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques

Gene Therapy ◽  
2001 ◽  
Vol 8 (7) ◽  
pp. 557-567 ◽  
Author(s):  
J D Eaton ◽  
M J A Perry ◽  
S M Todryk ◽  
R A Mazucco ◽  
R S Kirby ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Bystander Effect ◽  
Prodrug Activation ◽  
Rat Prostate ◽  
Activation Therapy

Microbial enzymes used in prodrug activation for cancer therapy: Insights and future perspectives

2020 ◽  
Vol 21 ◽  
Author(s):  
Rakhi Dhankhar ◽  
Anubhuti Kawatra ◽  
Aparajita Mohanty ◽  
Pooja Gulati
Keyword(s):  
Purine Nucleoside Phosphorylase ◽  
Cytosine Deaminase ◽  
Therapeutic Index ◽  
Enzyme Prodrug Therapy ◽  
Prodrug Activation ◽  
Microbial Enzymes ◽  
High Productivity ◽  
Delivery Vector ◽  
Exogenous Enzymes ◽  
Activation Therapy

Abstract:: Enzyme prodrug therapy has gained momentum in the recent years due to their ability to improve therapeutic index (benefits versus toxic side-effects) and efficacy of chemotherapy in cancer treatment. Inactive prodrugs used in this system are converted into active anti-cancerous drugs by enzymes, specifically within the tumor cells. This therapy involves three components namely prodrug, enzyme and gene delivery vector. Past reports have clearly indicated that the choice of enzyme used, is the major determinant for the success of this therapy. Generally, enzymes from non-human sources are employed to avoid off-target toxicity. Exogenous enzymes also give a better control to the clinician regarding the calibration of treatment by site-specific initiation. Amongst these exo-enzymes, microbial enzymes are preferred due to their high productivity, stability and ease of manipulation. The present review focuses on the commonly used microbial enzymes particularly cytosine deaminase, nitroreductase, carboxypeptidase, purine nucleoside phosphorylase in prodrug activation therapy. Various aspects viz. source of the enzymes, types of cancer targeted, mode of action and efficacy of the enzyme/prodrug system, efficient vectors used and recent research developments of each of these enzymes are comprehensively elaborated. Further, the results of the clinical trials and various strategies to improve their clinical applicability are also discussed.

scholarly journals The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancer

2000 ◽  
Vol 3 (S1) ◽  
pp. S10-S10
Author(s):  
JD Eaton ◽  
IA Clarke ◽  
H Pandha ◽  
AG Dalgleish ◽  
RS Kirby
Keyword(s):  
Prostate Cancer ◽  
Adenoviral Vectors ◽  
Prodrug Activation ◽  
Activation Therapy

Genetic Prodrug Activation Therapy for Pancreatic Cancer

1999 ◽  
Vol 880 (1 CELL AND MOLE) ◽  
pp. 319-325 ◽  
Author(s):  
A. S. RIGG ◽  
N. R. LEMOINE
Keyword(s):  
Pancreatic Cancer ◽  
Prodrug Activation ◽  
Activation Therapy

Developments in genetic prodrug activation therapy

1998 ◽  
Vol 1119 (1) ◽  
pp. 2-2
Keyword(s):  
Prodrug Activation ◽  
Activation Therapy

Genetic prodrug activation therapy: A novel treatment for cancer

1998 ◽  
Vol 23 (3) ◽  
pp. 279
Author(s):  
L.-A. Martin ◽  
H.S. Pandha ◽  
K. Sikora
Keyword(s):  
Prodrug Activation ◽  
Novel Treatment ◽  
Activation Therapy

scholarly journals Detection of Local Prostate Metabolites by Hrmas Nmr Spectroscopy: A Comparative Study of Human and Rat Prostate Tissues

2010 ◽  
Vol 4 ◽  
pp. MRI.S6028 ◽  
Author(s):  
Katarina Stenman ◽  
Izabella Surowiec ◽  
Henrik Antti ◽  
Katrine Riklund ◽  
Pär Stattin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Nmr Spectroscopy ◽  
Magnetic Resonance ◽  
Magic Angle Spinning ◽  
General Distribution ◽  
Resonance Spectroscopy ◽  
Magic Angle ◽  
Hrmas Nmr ◽  
Rat Prostate

The use of magnetic resonance spectroscopy (MRS) for the detection of in-vivo metabolic perturbations is increasing in popularity in Prostate Cancer (PCa) research on both humans and rodent models. However, there are distinct metabolic differences between species and prostate areas; a fact making general conclusions about PCa difficult. Here, we use High Resolution Magic Angle Spinning Nuclear Magnetic Resonance (HRMAS NMR) spectroscopy to provide tissue specific identification of metabolites and their relative ratios; information useful in providing insight into the biochemical pathways of the prostate. As our NMR-based approach reveals, human and rat prostate tissues have different metabolic signatures as reflected in numerous key metabolites, including citrate and choline compounds, but also aspartate, lysine, taurine, glutamate, glutamine, creatine and inositol. In general, distribution of these metabolites is not only highly dependent on the species (human versus rat), but also on the location (lobe/zone) in the prostate tissue and the sample pathology; an observation making HRMAS NMR of intact tissue samples a promising method for extracting differences and common features in various experimental prostate cancer models.

Genetic prodrug activation therapy

The Lancet ◽  
1997 ◽  
Vol 350 (9094) ◽  
pp. 1793-1794 ◽  
Author(s):  
LA Martin ◽  
R Vile ◽  
NR Lemoine ◽  
K Sikora ◽  
HS Pandha
Keyword(s):  
Prodrug Activation ◽  
Activation Therapy

Genetic prodrug activation therapy

1997 ◽  
Vol 3 (8) ◽  
pp. 359-366 ◽  
Author(s):  
Anne Rigg ◽  
Karol Sikora
Keyword(s):  
Prodrug Activation ◽  
Activation Therapy
Sign in / Sign up

Export Citation Format

Share Document